R&D

16 November 2015 · Press coverage

Pharco Pharma reports 100% HCV-4 cure rate with Sovaldi/ravidasvir combo in late-stage study

16 November 2015R&D
Pharco Pharma reports 100% HCV-4 cure rate with Sovaldi/ravidasvir combo in late-stage study

Late-stage study results documenting a complete cure rate for HCV-4 using a Sovaldi and ravidasvir combination therapy.

This item summarises coverage published by Press coverage.

Read the full article
Back to News & Events
R&DPharco Group

Press & media inquiries

For interview requests, image assets, or fact-checks, please contact our communications team directly.